BeiGene to Build New Manufacturing and Clinical R&D Facility in New Jersey

Published on: 

BeiGene plans to build a new campus for R&D and commercial-scale biopharmaceutical manufacturing in Hopewell, NJ.

On Aug 03, 2021, BeiGene, a global biotechnology company specializing in cancer therapeutics, announced plans to build a new campus for R&D and manufacturing in Hopewell, NJ. The company plans to acquire approximately 42 acres of land for the site, where it will build a facility for commercial-stage biopharmaceutical manufacturing and clinical R&D and where it will house the BeiGene Center for Pharmacovigilance Innovation. The acquisition of the property is expected to close in the third quarter of 2021, and construction of the campus is expected to be completed in mid-2023.

BeiGene said in a company press release that it chose Hopewell for its central location and proximity to deep and rich pharmaceutical research, development, and manufacturing talent. The site will also complement the company’s plans to expand its footprint in the region. BeiGene plans to recruit hundreds of new hires to support continued growth.

“We are proud to be building our campus in New Jersey, and we’re grateful for the warm welcome BeiGene has received across the state,” said John V. Oyler, co-founder, chairman, and CEO of BeiGene, in the press release. "With a global team of over 6900 and growing, including our existing presence in Ridgefield Park, NJ, BeiGene’s expansion into the Princeton area furthers our commitment of translating groundbreaking science into quality, innovative cancer therapies. We are excited to connect more with the deep talent pool in the region as we plan to diversify and further expand.”


“BeiGene continues to grow, and, as a key part of that growth, we are making a significant investment in the United States that will expand our current capabilities. This endeavor, once complete, will further expand and diversify our global supply chain and build new manufacturing capabilities for our world-class pipeline,” said Michael Garvey, global head of Technical Operations at BeiGene, in the press release. “We are excited to begin the planned construction of our buildings to house colleagues in a variety of disciplines as well as the manufacturing portion of the campus, which is expected to initially produce biologics and potentially small-molecule cancer treatments.”

Source: BeiGene